JUNIPER PHARMACEUTICALS INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 88 rows, 88 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-08-14: Reporting owner GERAGHTY JAMES A; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2018-08-14: Reporting owner GERAGHTY JAMES A; Form 4; Security Employee Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2018-08-14: Reporting owner Patel Nikin; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2018-08-14: Reporting owner Patel Nikin; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-08-14 | GERAGHTY JAMES A Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −30,000 0 owned after | $5.15 exercise price | 2018-08-15 | |
| 2018-08-14 | GERAGHTY JAMES A Director | 4 | Employee Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −70,000 0 owned after | $7.51 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 0 owned after | $7.90 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 0 owned after | $4.05 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −53,000 0 owned after | $5.15 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 0 owned after | $7.82 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32,000 0 owned after | $5.56 exercise price | 2018-08-15 | |
| 2018-08-14 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32,000 0 owned after | $7.05 exercise price | 2018-08-15 | |
| 2018-08-14 | Secor Alicia Director, Officer (President and CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −110,000 0 owned after | $7.90 exercise price | 2018-08-15 | |
| 2018-08-14 | Secor Alicia Director, Officer (President and CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −127,500 0 owned after | $5.15 exercise price | 2018-08-15 | |
| 2018-08-14 | Secor Alicia Director, Officer (President and CEO) | 4 | Nonqualified Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −225,000 0 owned after | $7.59 exercise price | 2018-08-15 | |
| 2018-08-14 | Young Jeffrey E Officer (Chief Financial Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,000 0 owned after | $7.90 exercise price | 2018-08-15 | |
| 2018-08-14 | Young Jeffrey E Officer (Chief Financial Officer) | 4 | Nonqualified Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −170,000 0 owned after | $5.60 exercise price | 2018-08-15 | |
| 2018-02-09 | Young Jeffrey E Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $7.90 exercise price | 2018-02-13 | |
| 2018-02-09 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $7.90 exercise price | 2018-02-13 | |
| 2018-02-09 | Secor Alicia Director, Officer (President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +110,000 110,000 owned after | $7.90 exercise price | 2018-02-13 | |
| 2017-04-11 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.05 exercise price | 2017-04-13 | |
| 2017-03-03 | GERAGHTY JAMES A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $5.15 exercise price | 2017-03-07 | |
| 2017-03-03 | Patel Nikin Director, Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +53,000 53,000 owned after | $5.15 exercise price | 2017-03-07 | |
| 2017-03-03 | Martell Bridget A Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +74,900 74,900 owned after | $5.15 exercise price | 2017-03-07 | |
| 2017-03-03 | Secor Alicia Director, Officer (President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +127,500 127,500 owned after | $5.15 exercise price | 2017-03-07 | |
| 2017-01-03 | Young Jeffrey E Officer (Chief Financial Officer) | 4 | Nonqualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +170,000 170,000 owned after | $5.60 exercise price | 2017-01-05 | |
| 2016-08-01 holding as of filing | Secor Alicia Director, Officer (President and CEO) | 3 | Nonqualified Stock Option (Right to Buy) Derivative · Direct | Holding | $7.59 exercise price | 2016-08-01 | ||
| 2016-02-19 | Elston George Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $7.82 exercise price | 2016-07-06 | |
| 2016-02-19 | Martell Bridget A Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $7.82 exercise price | 2016-07-06 | |
| 2016-02-19 | Patel Nikin Director, Officer (COO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $7.82 exercise price | 2016-07-06 | |
| 2016-02-19 | CONDELLA FRANK JR Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +110,000 110,000 owned after | $7.82 exercise price | 2016-07-06 | |
| 2015-05-26 | GERAGHTY JAMES A Director | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 70,000 owned after | $7.51 exercise price | 2015-06-01 | |
| 2015-05-11 | CONDELLA FRANK JR Officer (President & CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,375 9,375 owned after | $4.95 exercise price | 2015-05-12 | |
| 2015-02-11 | Patel Nikin Director, Officer (CEO, Molecular Profiles) | 4 | Employee Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,000 32,000 owned after | $5.56 | 2015-02-19 | |
| 2015-02-11 | CONDELLA FRANK JR Officer (President & CEO) | 4 | Employee Stock Option (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $5.56 | 2015-02-19 | |
| 2015-01-06 | Martell Bridget A Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $5.63 exercise price | 2015-01-09 | |
| 2014-10-01 | Elston George Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $5.97 exercise price | 2014-10-03 | |
| 2014-05-05 | LLOYD JONES JONATHAN BRIAN Officer (Vice President & CFO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 22,000 owned after | $5.04 exercise price | 2014-05-05 | |
| 2014-03-11 | LLOYD JONES JONATHAN BRIAN Officer (Vice President & CFO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 23,000 owned after | $5.04 exercise price | 2014-03-12 | |
| 2014-03-10 | CONDELLA FRANK JR Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $7.05 | 2014-03-12 | |
| 2014-03-10 | LLOYD JONES JONATHAN BRIAN Officer (Vice President & CFO) | 4 | Employee Stock Option Plan (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $7.05 | 2014-03-12 | |
| 2014-03-10 | Patel Nikin Director, Officer (CEO, Molecular Profiles) | 4 | Employee Stock Option Grant (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,000 32,000 owned after | $7.05 | 2014-03-11 | |
| 2013-03-01 | CONDELLA FRANK JR Director, Officer (President & CEO) | 4/A | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $0.62 | 2013-03-12 | |
| 2013-03-01 | CONDELLA FRANK JR Director, Officer (President & CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $0.62 | 2013-03-05 | |
| 2013-01-23 holding as of filing | LLOYD JONES JONATHAN BRIAN Officer (Vice President & CFO) | 3 | Employee Stock Option (Right to buy) Derivative · Direct | Holding | $0.64 exercise price | 2013-01-23 | ||
| 2012-02-29 | Gyenes Lawrence A Officer (Senior Vice President) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,000 135,000 owned after | $0.66 | 2012-03-01 | |
| 2012-02-29 | MCGRANE MICHAEL Officer (Senior Vice President) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,000 135,000 owned after | $0.66 | 2012-03-01 | |
| 2012-02-29 | Creasy George William II Officer (Vice President) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $0.66 | 2012-03-01 | |
| 2012-02-29 | CONDELLA FRANK JR Director, Officer (President & CEO) | 4/A | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +315,000 315,000 owned after | $0.66 | 2012-03-01 | |
| 2012-02-29 | COLUMBIA LABORATORIES INC Director, Officer (President and CEO) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +315,000 315,000 owned after | $0.66 | 2012-03-01 | |
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $6.46 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $4.05 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $2.05 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $2.75 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $4.34 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $1.42 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $2.40 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $3.00 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $1.33 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $1.07 exercise price | 2011-05-09 | ||
| 2011-05-09 holding as of filing | Creasy George William II Officer (VP, Clinical Research) | 3 | Stock Options Derivative · Direct | Holding | $2.59 exercise price | 2011-05-09 | ||
| 2011-02-07 | MCGRANE MICHAEL Officer (Senior VP & General Counsel) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,000 135,000 owned after | $2.59 | 2011-02-08 | |
| 2011-02-07 | Gyenes Lawrence A Officer (SVP, CFO) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,000 135,000 owned after | $2.59 | 2011-02-08 | |
| 2011-02-07 | CONDELLA FRANK JR Director, Officer (President and CEO) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +315,000 315,000 owned after | $2.59 | 2011-02-08 | |
| 2010-09-15 | CONDELLA FRANK JR Director, Officer (President and CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +350,000 350,000 owned after | $1.07 | 2010-09-16 | |
| 2010-09-15 | MCGRANE MICHAEL Officer (Senior VP & General Counsel) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.07 | 2010-09-16 | |
| 2010-09-15 | Gyenes Lawrence A Officer (SVP, CFO) | 4 | Employee stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.07 | 2010-09-16 | |
| 2009-12-11 | CONDELLA FRANK JR Director | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.87 exercise price | 2009-12-14 | |
| 2009-07-16 holding as of filing | Gyenes Lawrence A Officer (SVP, CFO) | 3/A | Employee stock option Derivative · Direct | Holding | $1.17 exercise price | 2009-07-16 | ||
| 2009-07-16 holding as of filing | Gyenes Lawrence A Officer (SVP, CFO) | 3 | Employee stock option Derivative · Direct | Holding | $1.17 exercise price | 2009-07-16 | ||
| 2009-03-11 | MILLS ROBERT S Director, Officer (President & CEO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +140,000 109,600 owned after | $1.33 exercise price | 2009-03-12 | |
| 2009-03-11 | Meer James Officer (Senior VP & CFO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +108,000 40,450 owned after | $1.33 exercise price | 2009-03-12 | |
| 2009-03-11 | MCGRANE MICHAEL Officer (Senior VP & General Counsel) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +108,000 96,237 owned after | $1.33 exercise price | 2009-03-12 | |
| 2009-02-17 | CAMPBELL ANTHONY R Director | 4 | Stock Option (right to buy) Derivative · Direct | J Other acquisition or disposition (describe transaction) | +25,000 25,000 owned after | $1.38 exercise price | 2009-02-19 | |
| 2008-03-03 | Meer James Officer (Senior VP & CFO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,000 30,100 owned after | $2.40 exercise price | 2008-03-03 | |
| 2008-03-03 | Meer James Officer (Senior VP & CFO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,000 30,100 owned after | $3.00 exercise price | 2008-03-03 | |
| 2008-03-03 | MCGRANE MICHAEL Officer (Senior VP & General Counsel) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,000 82,775 owned after | $2.40 exercise price | 2008-03-03 | |
| 2008-03-03 | MCGRANE MICHAEL Officer (Senior VP & General Counsel) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 82,775 owned after | $3.00 exercise price | 2008-03-03 | |
| 2008-03-03 | MILLS ROBERT S Director, Officer (President & CEO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 91,000 owned after | $2.40 exercise price | 2008-03-03 | |
| 2008-03-03 | MILLS ROBERT S Director, Officer (President & CEO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 91,000 owned after | $3.00 exercise price | 2008-03-03 | |
| 2007-05-15 | Crofton James Scott Director | 4 | Employee Stock Option Non-derivative · Direct | F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | −1,000 8,000 owned after | $2.21 | 2007-05-17 | |
| 2007-02-28 | MCGRANE MICHAEL Officer (Sr. Vice President and Secy.) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +240,000 240,000 owned after | $1.42 exercise price | 2007-03-02 | |
| 2007-02-28 | Meer James Officer (Sr. Vice President CFO & Treas) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +210,000 210,000 owned after | $1.42 exercise price | 2007-03-02 | |
| 2007-02-28 | MILLS ROBERT S Director, Officer (Chief Executive Officer) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $1.42 exercise price | 2007-03-02 | |
| 2006-12-08 holding as of filing | Meer James Officer (Senior Vice President CFO) | 3 | Incentive Stock Option (right to buy) Derivative · Direct | Holding | $4.29 exercise price | 2006-12-08 | ||
| 2006-12-08 holding as of filing | Meer James Officer (Senior Vice President CFO) | 3 | Non-Qualified Stock Option (right to buy) Derivative · Direct | Holding | $4.29 exercise price | 2006-12-08 | ||
| 2006-09-13 | BLECHSCHMIDT EDWARD A Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | C Conversion of derivative security | −10,000 0 owned after | $2.14 exercise price | 2006-09-14 | |
| 2006-08-15 | KASNET STEPHEN G Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | C Conversion of derivative security | −10,000 0 owned after | $2.14 exercise price | 2006-08-15 | |
| 2006-08-15 | KASNET STEPHEN G Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | C Conversion of derivative security | −2,000 0 owned after | $2.37 exercise price | 2006-08-15 | |
| 2006-05-15 | MILLS ROBERT S Director, Officer (Chief Executive Officer) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $4.34 exercise price | 2006-05-17 | |
| 2006-05-15 | WEINBERG DAVID L Officer (Vice President and CFO) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $4.34 exercise price | 2006-05-17 | |
| 2006-05-15 | MCGRANE MICHAEL Officer (Sr. Vice President and Secy.) | 4 | Employee Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $4.34 exercise price | 2006-05-17 |